Camoteskimab is a Monoclonal Antibody owned by Apollo Therapeutics, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.
Camoteskimab (AEVI-007) acts by inhibiting interleukin-18 (IL-18). IL-18 is a pro-inflammatory cytokine involved in both innate and acquired immune responses. MEDI2338 binds to human IL-18 and blocks the interaction with the IL-18R. It modulates disease relevant mediators.
The revenue for Camoteskimab is expected to reach a total of $61m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Camoteskimab NPV Report.
Camoteskimab was originated by MedImmune and is currently owned by Apollo Therapeutics. Avalo Therapeutics is the other company associated in development or marketing of Camoteskimab.
Camoteskimab (AEVI-007) is under development for adult onset Still’s disease (Rheumatoid arthritis) and relapsed or refractory multiple myeloma. It is administered intravenously as water for injection. It is a fully humanized monoclonal antibody acts by targeting interleukin 18. It was under development for the treatment chronic obstructive pulmonary disease (COPD).
Avalo Therapeutics Overview
Avalo Therapeutics, formerly Cerecor is a biopharmaceutical company that develops and commercializes novel products in the fields of neurology and pediatrics. The company’s products include prescription medications, prescription devices and dietary supplements. Its pipeline products offer treatment in the areas of neurogenic orthostatic hypotension, parkinsons disease, seizures in epilepsy and deoxyguanosine kinase deficiency. Avalo Therapeutics‘ prescription medications comprise aciphex sprinkle, cefaclor, millipred tablets and dose packs and millipred oral solution, among others. The company also offers dietary supplements such as chewable tablets and drops. Avalo Therapeutics is headquartered in Baltimore, Maryland, the US.
The company reported revenues of (US Dollars) US$5.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 19.4% over FY2020. The operating loss of the company was US$82.1 million in FY2021, compared to an operating loss of US$72.8 million in FY2020. The net loss of the company was US$84.4 million in FY2021, compared to a net loss of US$63.5 million in FY2020. The company reported revenues of US$1 million for the second quarter ended June 2022, a decrease of 11.9% over the previous quarter.
Quick View – Camoteskimab
|Highest Development Stage|